Quarterly report pursuant to Section 13 or 15(d)

LIQUIDITY (Details)

v3.24.1.1.u2
LIQUIDITY (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Nov. 14, 2023
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Jun. 30, 2023
Accumulated deficit   $ (306,468)   $ (306,468)   $ (260,985)
Net Income (Loss)   (17,050) $ (15,672) (45,483) $ (39,059) (51,800)
Net cash used in operating activities       (38,846) $ (33,131) (44,500)
Cash and cash equivalents   5,930   5,930   16,036
Short-term investments   74,092   74,092   85,860
Long-term investments   1,573   1,573   16,470
Total liabilities   16,876   16,876   7,549
Current liabilities   $ 6,957   6,957   $ 5,200
At the Market Offering            
Amount agreed to sell as per open market sales agreement $ 50,000          
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Scenario, Upon First Dosing Of The First Patient            
Milestone closing payment       5,000    
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Scenario, Upon Dosing Of The Last Patient [Member]            
Milestone closing payment       $ 5,000